John H. Hutchinson

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

J. S. Swaney, Charles W. Chapman, Lucia Correa et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 126 citations

Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(<i>t</i>-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor

Christine Brideau, Christine Chan, S. Charleson et al. · Canadian Journal of Physiology and Pharmacology · 1992 · 112 citations

Lipid Peroxidation, Whole Blood, Experimental Pharmacology +17

Nonpeptide α_vβ₃ Antagonists. 8. In Vitro and in Vivo Evaluation of a Potent α_vβ₃ Antagonist for the Prevention and Treatment of Osteoporosis

John H. Hutchinson, Wasyl Halczenko, Karen M. Brashear et al. · Journal of Medicinal Chemistry · 2003 · 96 citations · Full text

Pharmacotherapy, Osteoporosis, Selective Antagonist +17

Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX

John H. Hutchinson, Martin W. Rowbottom, David Lonergan et al. · ACS Medicinal Chemistry Letters · 2017 · 82 citations · Full text

Nonpeptide α_vβ₃ Antagonists. Part 11:  Discovery and Preclinical Evaluation of Potent α_vβ₃ Antagonists for the Prevention and Treatment of Osteoporosis

Paul J. Coleman, Karen M. Brashear, Ben Askew et al. · Journal of Medicinal Chemistry · 2004 · 79 citations · Full text

Pharmacotherapy, Experimental Pharmacology, Osteoporosis +16